Table 1.
Clinicopathological features of breast cancer patients studied
| n=96 | Prior to chemotherapy | After chemotherapy | ||
|---|---|---|---|---|
|
Tumour size |
1,5-13 cm |
0,3-14 cm |
||
| |
cT1 |
1 (1%) |
ypT0 |
6 (6%) |
| |
-a |
|
ypT1 |
20 (21%) |
| |
-b |
|
-a |
2 |
| |
-c |
1 |
-b |
11 |
| |
cT2 |
25 (26%) |
-c |
7 |
| |
cT3 |
22 (23%) |
ypT2 |
31 (32%) |
| |
cT4 |
41 (43%) |
ypT3 |
24 (25%) |
| |
-b |
19 |
ypT4 |
7 (7%) |
| |
-d |
22 |
-b |
6 |
| |
NA |
7 (7%) |
-d |
1 |
| |
|
|
No surgery |
8 (9%) |
|
Lymph node status |
cN0 |
10 (11%) |
pN0 |
25 (26%) |
| |
cN1 |
62 (64%) |
pN1 |
27 (28%) |
| |
cN2 |
|
pN2 |
12 (12%) |
| |
cN3 |
3 (3%) |
pN3 |
14 (15%) |
| |
|
|
No surgery |
8 (9%) |
| |
NA |
21 (22%) |
NA |
10 (10%) |
|
ER status |
Positive |
68 (71%) |
Positive |
59 (62%) |
| |
Negative |
25 (26%) |
Negative |
16 (17%) |
| |
NA |
3 (3%) |
NA |
21 (21%) |
| |
|
|
ypT0, no surgery |
|
|
PR status |
Positive |
59 (62%) |
Positive |
46 (48%) |
| |
Negative |
34 (35%) |
Negative |
29 (31%) |
| |
NA |
3 (3%) |
NA |
21 (21%) |
| |
|
|
ypT0, no surgery |
|
|
HER2 status |
Positive |
28 (29%) |
Positive |
18 (19%) |
| |
Negative |
65 (68%) |
Negative |
57 (60%) |
| |
NA |
3 (3%) |
NA |
21 (21%) |
| |
|
|
ypT0, no surgery |
|
|
Ki67 status |
0 |
2 (2%) |
0 |
22 (28%) |
| |
1 (0-1%) |
12 (15%) |
1 |
21 (27%) |
| |
2 (1-5%) |
19 (23%) |
2 |
11 (14%) |
| |
3 (5-10%) |
13 (16%) |
3 |
3 (4%) |
| |
4 (10-15%) |
6 (7%) |
4 |
1 (1%) |
| |
5 (15-20%) |
4 (5%) |
5 |
6 (8%) |
| |
6 (20-33%) |
2 (2%) |
6 |
1 (1%) |
| |
7 (33-50%) |
4 (5%) |
7 |
2 (3%) |
| |
8 (50-66%) |
1 (1%) |
8 |
0 (0%) |
| |
9 (66-80%) |
3 (4%) |
9 |
3 (4%) |
| |
10 (80-100%) |
1 (1%) |
10 |
2 (3%) |
| |
NA |
14 (17%) |
NA |
7 (9%) |
| ∑ | 64+17 (100%) | ∑ | 64+15 (100%) | |
NA: Accurate data are not available.